LIC raises stake in Dr. Reddy’s
The Hindu
LIC increases stake in Dr. Reddy's Labs to over 8%, acquiring more than 2% since October 2024.
Life Insurance Corporation of India’s stake in Dr. Reddy’s Laboratories raced past the 8% mark recently with the country’s largest institutional investor acquiring an additional, more than 2% in the generic drugmaker since October 2024.
From about 6.20%, the holding increased to 8.21% in a period of less than eight months through open market purchases. In terms of number of shares, LIC had acquired more than 1.67 crore during this period, the Hyderabad-headquartered pharma major said in a filing.
Dr. Reddy’s shares closed 3.01% higher on Thursday at ₹1,289.90 apiece on the BSE.

According to recent Foreign Trade Performance Analysis data, India’s overall exports remained resilient in late 2025, even as traditional sectors faced sharp declines. While shipments of gems and jewellery to the U.S. plummeted, the overall figures were bolstered by a massive 237% surge in telecom exports, particularly smartphones. Data shows that Indian exporters are aggressively diversifying their portfolios. By deepening ties with existing partners and discovering new alliances, India is replacing lost U.S. sales with a more diversified set of trade partners












